<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C2E5B7D2-39A5-49A6-8EA0-5945E50AE2BB"><gtr:id>C2E5B7D2-39A5-49A6-8EA0-5945E50AE2BB</gtr:id><gtr:firstName>Matthew</gtr:firstName><gtr:surname>Cotten</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U190085856"><gtr:id>43B475E4-DE72-49A5-9EA7-84907D33B0F5</gtr:id><gtr:title>TRIM5a and HIV-2 infection: p26 genetic variability that may influence disease progression</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U190085856</gtr:grantReference><gtr:abstractText>Lay summary not currently available</gtr:abstractText><gtr:technicalSummary>Recent studies have identified endogenous mammalian systems that block or restrict retroviral infection. One such pathway involves host proteins that interact with viral capsid protein and block subsequent stages of the infection. The aims of this study are to examine the capsid sequence of HIV isolates, to examine the TRIM5? variability in a cohort, and to determine if p26 and TRIM5? protein differences influence replication levels in 200 patients and controls from Caio Guinea Bissau. HIV-2 capsid gene sequences from currently circulating viruses were determined by reverse transcriptase polymerase chain reaction and coupled by nest PCR to amplify p26 region.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>724457</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>HIV sequence data</gtr:description><gtr:id>E44D3F69-FE8B-4CB5-8CFA-E1B8CD38A61D</gtr:id><gtr:impact>Difficult to answer this question.</gtr:impact><gtr:outcomeId>AswkMTbynF9</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HIV sequence data</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1D0D8EC9-9E2B-435B-9AF0-631695221755</gtr:id><gtr:title>Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0ae9c03e19152fa146debeb3e0a9814"><gtr:id>c0ae9c03e19152fa146debeb3e0a9814</gtr:id><gtr:otherNames>Leligdowicz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>CLNwjhKL89o</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF0AD063-FEE5-49DF-A126-541AE64D517B</gtr:id><gtr:title>Highly avid, oligoclonal, early-differentiated antigen-specific CD8+ T cells in chronic HIV-2 infection.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0ae9c03e19152fa146debeb3e0a9814"><gtr:id>c0ae9c03e19152fa146debeb3e0a9814</gtr:id><gtr:otherNames>Leligdowicz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>ZNGEHJRDvLf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>989E9A32-AC40-499E-82C5-E69A2E0C51B7</gtr:id><gtr:title>Direct relationship between virus load and systemic immune activation in HIV-2 infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0ae9c03e19152fa146debeb3e0a9814"><gtr:id>c0ae9c03e19152fa146debeb3e0a9814</gtr:id><gtr:otherNames>Leligdowicz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>V4t5s9k6spu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBA6C9D7-9390-4E79-B2F3-65F89AC55525</gtr:id><gtr:title>HIV-1 subtype distribution in the Gambia and the significant presence of CRF49_cpx, a novel circulating recombinant form.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7219e699c28c45d6e339476809f7f10"><gtr:id>c7219e699c28c45d6e339476809f7f10</gtr:id><gtr:otherNames>de Silva TI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>ZxbvojYwSQz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CA5CA1C-8F9E-4AF5-8A4B-62E488CC298E</gtr:id><gtr:title>HIV-2 capsids distinguish high and low virus load patients in a West African community cohort.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3094c394a39ea9ab41112106da91aea3"><gtr:id>3094c394a39ea9ab41112106da91aea3</gtr:id><gtr:otherNames>Onyango CO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>ayM8LRt9hMs</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U190085856</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>